Objectives To assess the cost-effectiveness of dabigatran versus rivaroxaban for the
prevention of stroke and systemic embolism in Chinese patients with non-valvular atrial …

Abstract Purpose In China, dabigatran and rivaroxaban are the only approved non–vitamin
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …

Objectives The novel oral anticoagulants (NOACs) including apixaban, dabigatran and
rivaroxaban have been widely applied to anticoagulation treatment for non-valvular atrial …

Objectives In the US, dabigatran etexilate (dabigatran) and rivaroxaban are two new
treatments for reducing risk of stroke and systemic embolism (SE) in patients with non …

Background and objective: To evaluate the cost-effectiveness of new anticoagulants and
warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF). Methods …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Background and objective To evaluate the cost-effectiveness of new anticoagulants and
warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF). Methods …

What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …

Objectives To evaluate the cost-effectiveness of the novel anticoagulant rivaroxaban versus
the current standard of care, warfarin, for stroke prevention in nonvalvular atrial fibrillation …

Objectives To evaluate the cost-effectiveness of rivaroxaban over real-world treatment
prescribing scenario (ie 23% of patients receiving warfarin, 57% of patients receiving …